US 11,993,573 B2
Chromane-substituted, tetrahydroquinoline-substituted and thiochromane-substituted heteroarotinoids as anti-cancer agents
Kenneth Darrell Berlin, Stillwater, OK (US); Richard A. Bunce, Stillwater, OK (US); Krishna Kumar Gnanasekaran, Mississauga (CA); Field M. Watts, Jr., Fort Smith, AR (US); and Donghua Howard Zhou, Edmond, OK (US)
Assigned to THE BOARD OF REGENTS FOR OKLAHOMA STATE UNIVERSITY, Stillwater, OK (US)
Filed by THE BOARD OF REGENTS FOR OKLAHOMA STATE UNIVERSITY, Stillwater, OK (US)
Filed on Feb. 4, 2021, as Appl. No. 17/167,251.
Application 17/167,251 is a division of application No. 16/549,337, filed on Aug. 23, 2019, granted, now 10,947,198.
Claims priority of provisional application 62/722,294, filed on Aug. 24, 2018.
Prior Publication US 2021/0163415 A1, Jun. 3, 2021
Int. Cl. A61P 35/00 (2006.01); A61K 31/352 (2006.01); A61K 31/382 (2006.01); A61K 31/47 (2006.01); C07D 215/06 (2006.01); C07D 311/70 (2006.01); C07D 335/06 (2006.01)
CPC C07D 215/06 (2013.01) [A61K 31/352 (2013.01); A61K 31/382 (2013.01); A61K 31/47 (2013.01); A61P 35/00 (2018.01); C07D 311/70 (2013.01); C07D 335/06 (2013.01)] 4 Claims
 
1. A method of treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound
selected from the group consisting of

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry
or a salt, solvate, or hydrate thereof.